D
Oruka Therapeutics, Inc. ORKA
$34.39 -$1.14-3.21% NASDAQ
Recommendation
Prev Close
$35.53
Volume
472,910
Avg Vol (90D)
549,048
Market Cap
$1.72B
Dividend & Yield
--
52-Week Range
$5.49 - $36.51
P/E (TTM)
--
EPS (TTM)
-$1.94
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Oruka Therapeutics (ORKA, $35.53) RSI Indicator left the overbought zone on January 22, 2026
1/23/2026 - Tickeron - Stocks
Oruka Therapeutics (NASDAQ:ORKA) Shares Gap Down - Here's What Happened
1/22/2026 - MarketBeat
Secure Asset Management, LLC Buys 81,664 Shares of Oruka Therapeutics Inc (ORKA)
1/21/2026 - GuruFocus
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week High - What's Next?
1/21/2026 - MarketBeat
Assessing Oruka Therapeutics (ORKA) Valuation After Encouraging ORKA 002 Phase 1 Trial Results
1/19/2026 - Simply Wall St
Short Interest in Oruka Therapeutics, Inc. (NASDAQ:ORKA) Rises By 30.8%
1/18/2026 - Ticker Report
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Update
1/18/2026 - MarketBeat
Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells 7,000 Shares of Stock
1/17/2026 - MarketBeat
Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock
1/17/2026 - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,000 Shares
1/17/2026 - Ticker Report
Oruka Therapeutics (ORKA) Is Up 23.1% After Extended-Dosing IL-17 Data for ORKA-002 - What's Changed
1/16/2026 - Simply Wall St
Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month High - Here's Why
1/15/2026 - MarketBeat
Oruka Therapeutics (ORKA, $31.34) Moving Average Convergence Divergence (MACD) Histogram turned positive on January 13, 2026
1/14/2026 - Tickeron - Stocks
ORKA: Wedbush Raises Price Target for Oruka Therapeutics ORKA Stock News
1/13/2026 - GuruFocus
Oruka Therapeutics price target raised by $3 at Wedbush, here's why
1/13/2026 - The Fly
BTIG Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)
1/13/2026 - TipRanks Financial Blog
Oruka Therapeutics price target raised to $71 from $46 at Clear Street
1/13/2026 - TipRanks Financial Blog
Oruka Therapeutics price target raised by $25 at Clear Street, here's why
1/13/2026 - The Fly
BTIG Research Issues Positive Forecast for Oruka Therapeutics (NASDAQ:ORKA) Stock Price
1/12/2026 - MarketBeat
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of ...
1/12/2026 - GuruFocus
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
1/12/2026 - Globe Newswire
Noteworthy Friday Option Activity: ORKA, FIVE, PCT
1/9/2026 - Stock Options Channel
Oruka Therapeutics (NASDAQ:ORKA) Raised to "Strong-Buy" at UBS Group
1/9/2026 - Ticker Report
Oruka Therapeutics (NASDAQ:ORKA) Rating Increased to Strong-Buy at UBS Group
1/9/2026 - MarketBeat
Does UBS's New Coverage Reframe Oruka Therapeutics (ORKA) as a Peptide Platform, Not Just a Biotech?
1/8/2026 - Simply Wall St
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$125.00M
EBIT (TTM)
-$125.08M
Net Income (TTM)
-$109.24M
Balance Sheet
Total Assets (Q)
$509.25M
Total Debt (Q)
$1.91M
Total Liabilities (Q)
$22.46M
Book Value Per Share (Q)
$10.00
Cash Flow
Cash from Operations (TTM)
-$89.69M
Cash from Investing (TTM)
-$434.69M
Cash from Financing (TTM)
$210.36M
Net Change in Cash (TTM)
-$314.02M
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 2 and 6 (est)
Price History
Loading...
Beta
--
7-Day Total Return
9.73%
30-Day Total Return
11.69%
60-Day Total Return
24.15%
90-Day Total Return
125.36%
Year to Date Total Return
21.65%
1-Year Total Return
175.78%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 09, 2025 - $5.49
52-week High
Jan 22, 2026 - $36.51
Valuation
Market Cap
$1.72B - Small Cap
Enterprise Value
$1.22B
Price/Sales (TTM)
--
Price/Book (Q)
3.55
Dividends and Shares
Shares Outstanding
44.07M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
orukatx.com
Phone Number
650 606 7910
Address
855 Oak Grove Avenue
Menlo Park, CA 94025
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I)... more
NASDAQ 01/23/2026 4:00PM Eastern Quotes delayed